NutraNomics Receives Initial Purchase Order for New Weight Loss Line of Products
DRAPER, UT--(Marketwired - Aug 27, 2014) - NutraNomics (OTCBB: NNRX) is pleased to announce the receipt of an initial purchase order in August totaling $233,000 for a new weight loss line of products formulated by Dr. Tracy Gibbs, NutraNomics's founder, in the spring of 2014. The purchase order was placed by a large Utah-based multi-level marketing company, and it is anticipated that the company will be announcing the launch of this line under their own brand this coming September. NutraNomics will retain exclusive manufacturing rights for the line of products, and NutraNomics hopes to be able to create and supply many more products for the company in the future.
"The quick lead time between the development and the sale of this line of products represents the skill that Dr. Gibbs and the rest of our team has here at NutraNomics," stated Mike Brousseau, General Manager of NutraNomics. "We've coordinated the formulation, raw material supply and production of this line within a three-month time span, showcasing our expertise."
Management believes that this new relationship will not only increase revenue, but improve the profitability of NutraNomics. "Because our new client has operations in many countries around the world, we expect the new relationship to increase our footprint in the EU and Latin America, where we have only a small number of clients," said Mr. Brousseau.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements," which include statements that are not purely historical or are regarding beliefs, plans, expectations or intentions. Actual results could differ from those in any forward-looking statements due to numerous factors, including the uncertainties associated with developing and marketing new products, operating as a development stage company, competition, and market conditions. These forward-looking statements are made as of the date hereof, and we assume no obligation to update the statements except as required by law. Although we believe that any beliefs, plans, expectations or intentions contained herein are reasonable, there can be no assurance that they will prove to be accurate. Investors should refer to all of the information and risk factor disclosure in our reports filed with the SEC, available at www.sec.gov.
These statements have not been evaluated by the Food and Drug Administration. The company's products are not intended to diagnose, treat, cure or prevent any disease.
